Information  X 
Enter a valid email address

Byotrol PLC (BYOT)

  Print          Annual reports

Monday 13 December, 2021

Byotrol PLC

Directorate Change

RNS Number : 3557V
Byotrol PLC
13 December 2021
 

Byotrol plc ("Byotrol" or the "Company")

Directorate Change

Byotrol plc (AIM: BYOT), the infection prevention technology company, is pleased to announce the appointment of Chris Sedwell as CFO of the Company. Chris joins the Board of Directors with immediate effect. 

Nic Hellyer, part-time CFO since May 2019 has now formally left the Company, but will continue to be available to assist in an orderly handover process.

Chris is ACA trained and an ICAEW fellow. He was most recently Portfolio Finance Director of FD & CFO Centre, working with various SMEs to provide finance consultancy. For the preceding six years he was Finance Director of ConvaTec Limited, a FTSE250 listed medical products and technologies business. Prior to this, he was Head of Finance & Administration at Iceland International, a part of the UK supermarket chain Iceland Foods Group.

At the date of this announcement, Mr Sedwell does not have any beneficial interest in the ordinary shares of the Company.

 

Commenting on the appointment, John Langlands, Chairman of Byotrol plc, said:

"We are very pleased to welcome Chris Sedwell to the Board of Byotrol.  He has a wealth of highly relevant industrial and healthcare experience, from listed company to SME.  We are convinced that he will be a very important asset to the Company as we continue to grow and develop.

We thank Nic Hellyer for his service to the Company and wish him every success for the future."

 

Enquiries:

 

Byotrol Plc


John Langlands - Chairman

David Traynor - Chief Executive

+44 (0)1925 742 000



finnCap (Nominated Adviser and Broker)

+44 (0)20 7220 0500

Geoff Nash/Kate Bannatyne - Corporate Finance


Richard Chambers - ECM




Flagstaff Strategic and Investor Communications

+44 (0)20 7129 1474

Tim Thompson/Andrea Seymour/Fergus Mellon    

 

[email protected]

 

 

Notes to Editors:

 

Byotrol plc (BYOT.L), quoted on AIM, is a specialist infection prevention and control company, operating globally in the Healthcare, Industrial, Food and Consumer sectors, providing low toxicity products with a broad-based and targeted efficacy across all microbial classes; bacteria, viruses (including coronavirus), fungi, moulds, mycobacteria and algae.

 

Byotrol's products can be used stand-alone or as ingredients within existing products, where they can significantly improve their performance, especially in personal hygiene, domestic and industrial disinfection, odour control, food production and food management.

 

Byotrol develops and commercialises technologies that create easier, safer and cleaner lives for everyone.

 

For more information, please go to byotrol.co.uk

 

 

 

Christopher John Sedwell, aged 45, is, or has been within the last five years, a director or partner in the following companies and partnerships:

 

 

Current directorships and partnerships

Previous directorships and partnerships held within the last five years

S edwell Consulting Limited

C onvaTec Limited

Unomedical Holdings Limited

C onvaTec Accessories Limited

Unomedical Limited

Amcare Limited

Alpha-Med (Medical & Surgical) Limited

SureCalm Healthcare Limited

SureCalm Pharmacy Limited

Surecalm Healthcare Holdings Limited

B.C.A Direct Limited

Resus Positive Limited

Akers & Dickinson Limited

Novacare UK Limited

Unomedical Developments Limited

Unoplast (UK) Limited

Steriseal Limited

Pharma-Plast Limited

Farnhurst Medical Limited

ConvaTec Speciality Fibres Limited

Nottingham Medical Equipment Limited

Needle Industries (Sheffield) Limited

Lance Blades Limited

M.S.B Limited

Rotax Razor Company Limited

Arthur Wood Limited

Allied Medical Services (UK) Limited

Bradgate-Unitech Limited

Shrimpton & Fletcher Limited

 

There are no further disclosures regarding Chris Sedwell pursuant to Rule 17 and Schedule 2(g) of the AIM Rules for Companies.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAEAXAAFAAFFFA

a d v e r t i s e m e n t